Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of oncology assets and strong track-record of commercial execution, and BridgeBio Pharma Inc., a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, have updated their existing strategic collaboration to develop, manufacture and commercialize infigratinib for oncology indications. Terms of the Agreement Under the terms of the amended and restated agreement, Helsinn wi...